New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th, 2025, including 180mg Q8W cohort Company to host conference call ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

The Global Cough Remedies Market is valued at approximately USD 7.83 billion in 2023 and is projected to grow with a steady CAGR of 3.9% over the forecast period 2024-2032. Request To Download Free ...

Know, though, that even when the cause can't be identified, treatment can help control symptoms and provide relief ...

As we enter the final few months of the year, Noah Kahan’s Stick Season holds on to its title as the biggest song of 2024 so far, Official Charts can reveal. However, with several new entries ...

Gum disease is a common issue for many adults, possibly causing red or bleeding gums. Treatment may involve cleaning bacteria from under the gums and maintaining good dental hygiene at home.

The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent ... Dupixent is also approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal ...

People may be able to nurse after breast cancer treatment. However, these treatments may affect the structure of the breast and milk supply, which can hinder the ability to nurse. The ability to ...

(NASDAQ: REGN) and Sanofi today announced that the National Medical Products Administration (NMPA) in China has approved Dupixent ® (dupilumab) as an add-on maintenance treatment for adults with ...

Obesity increases the risk of nearly 200 diseases and can cause serious health conditions like asthma, strokes ... stigma-free obesity prevention and treatment programs, and evidence-based ...

Their analysis shows that children's risk of developing asthma later in life can be more reliably predicted by observing the dynamic development of symptoms during the first year of life.